한글목차

콕시디오이데스증 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 3억 5,000만 달러에서 2026년에는 3억 8,000만 달러로, CAGR 7.8%로 확대될 것으로 예상됩니다. 지난 몇 년간의 성장은 곰팡이 감염 발생률 증가, 플루코나졸의 광범위한 사용, 감염 전문 클리닉의 확대, 진단 검사의 개선, 면역 결핍 상태에 있는 인구의 증가 등이 원인으로 추정됩니다.

콕시디오이데스증 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 7.7%의 CAGR로 5억 1,000만 달러에 달할 전망입니다. 예측 기간의 성장 요인으로는 기후변화에 따른 질병 확산, 밸리열(콕시디오이데스증)에 대한 인식 개선, 항진균제 개발의 진전, 전문 진료소 확대, 의료 접근성 향상 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 아졸계 항진균제 사용 증가, 장기 항진균제 치료에 대한 관심 증가, 유행 지역에서의 진단 건수 증가, 병원 기반 감염 치료 확대, 면역결핍증 환자에 대한 관심 증가 등이 있습니다.

향후 몇 년 동안 면역결핍증 환자의 증가는 콕시디오이데스증 치료제 시장의 성장을 견인할 것으로 예상됩니다. 면역부전 상태란 면역체계가 약화되어 감염이나 질병(인체면역결핍바이러스(HIV) 감염, 암, 장기 이식 병력 등)에 대한 취약성이 높아진 상태를 말합니다. 만성질환 유병률 증가, 장기 이식 건수 증가, 면역억제요법의 보급, 인간면역결핍바이러스(HIV)/후천성면역결핍증후군(AIDS) 발생률 증가 등의 요인으로 인해 면역결핍 상태의 인구가 증가하고 있습니다. 콕시디오이데스증 치료제는 면역기능이 저하된 환자에게 곰팡이 감염을 조절하고 질병의 중증도를 낮추며, 생명을 위협할 수 있는 파종성 콕시디오이데스증과 같은 합병증을 예방하는 데 도움이 됩니다. 예를 들어, 스위스에 본부를 둔 유엔기구인 유엔합동에이즈계획(UNAIDS)에 따르면, 2024년 7월 기준 2023년 HIV 감염자 수는 약 3,990만 명으로 2022년 3,900만 명에서 증가했다고 합니다. 이처럼 면역력이 약한 사람들이 증가하면서 콕시디오이데스증 치료제 시장 확대에 힘을 실어주고 있습니다.

콕시디오이데스증 치료제 시장에서 활동하는 주요 기업들은 증가하는 발병률과 약제 내성에 대응하기 위해 키틴 합성효소 억제제 및 차세대 전신성 약물을 포함한 혁신적인 항진균 치료제와 백신에 대한 연구개발 투자를 강화하고 있습니다. 키틴 합성효소 억제제는 곰팡이의 키틴 합성효소를 표적으로 하는 치료 화합물로 곰팡이의 세포벽 형성을 억제하여 콕시듐 디오이드 속 균의 생존율을 감소시킵니다. 예를 들어, 2025년 6월 미국 바이오텍 기업 Valley Fever Solutions는 흡입 투여 가능한 약물 NikZ(니코마이신 Z)의 I/II상 임상시험에 돌입했습니다. 본 제제는 급성 및 만성 감염에 대한 강력한 키틴 합성효소 억제 작용을 가지고 있으며, 희귀질환치료제 지정을 획득했습니다. 치료 기간 단축과 효과 향상을 목표로 하고 있습니다. 정부 기관의 추가 지원도 받고 있습니다. 미국 국립알레르기감염병연구소(NIAID)는 2025 밸리피버 전략 계획을 통해 임상시험 인프라, 백신 연구, 항진균제 혁신을 지속적으로 지원하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

A coccidioidomycosis drug is a medication developed to treat infections caused by Coccidioides species, the fungi that lead to valley fever. These drugs, including azole antifungals and polyene antifungals, work to inhibit fungal growth and alleviate symptoms. Depending on the infection's severity, treatment may be administered orally, intravenously, or over a prolonged period to prevent complications, particularly in immunocompromised individuals.

The primary categories of drugs for treating coccidioidomycosis include azoles, echinocandins, and polyenes. Azoles are a group of antifungal medications that work by blocking the production of ergosterol, a vital component of fungal cell membranes. Treatment can be administered through oral or intravenous routes, with specific phases including the acute phase, chronic phase, and preventive therapy. Patients are classified as either immunocompetent or immunocompromised, while end-users consist of specialty clinics, hospitals, homecare services, and other care settings.

Tariffs have increased the cost of imported antifungal APIs and finished formulations used in the production of azole based therapies. The impact is strongest in azole drug segments, where manufacturing scale and pricing sensitivity are high. Regions such as North America have experienced higher input costs due to reliance on cross border pharmaceutical sourcing. Rising tariff related expenses have influenced production economics, pricing strategies, and procurement planning for antifungal treatments. Tariffs have supported local pharmaceutical manufacturing, expanded domestic production capacity, and strengthened regional drug supply chains over the long term.

The coccidioidomycosis drug market research report is one of a series of new reports from The Business Research Company that provides coccidioidomycosis drug market statistics, including coccidioidomycosis drug industry global market size, regional shares, competitors with a coccidioidomycosis drug market share, detailed coccidioidomycosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the coccidioidomycosis drug industry. This coccidioidomycosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coccidioidomycosis drug market size has grown strongly in recent years. It will grow from $0.35 billion in 2025 to $0.38 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing fungal infection incidence, widespread fluconazole usage, expansion of infectious disease clinics, improved diagnostic testing, rising immunocompromised population.

The coccidioidomycosis drug market size is expected to see strong growth in the next few years. It will grow to $0.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to climate-related disease spread, rising awareness of valley fever, growth in antifungal drug development, expansion of specialty clinics, increasing healthcare access. Major trends in the forecast period include rising use of azole antifungal therapies, increasing focus on long-term antifungal treatment, growing diagnosis in endemic regions, expansion of hospital-based infectious disease care, increased attention to immunocompromised patients.

The rising number of immunocompromised individuals is expected to drive the growth of the coccidioidomycosis drug market in the coming years. Immunocompromised individuals are those with weakened immune systems, making them more vulnerable to infections and illnesses, including those affected by human immunodeficiency virus (HIV), cancer, or prior organ transplants. The immunocompromised population is increasing due to factors such as the growing prevalence of chronic diseases, higher numbers of organ transplants, widespread use of immunosuppressive therapies, and the rising incidence of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). Coccidioidomycosis drugs assist immunocompromised patients by controlling fungal infections, reducing disease severity, and preventing complications like disseminated coccidioidomycosis, which can be life-threatening due to their weakened immune response. For example, in July 2024, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based United Nations organization, around 39.9 million people were living with HIV in 2023, up from 39.0 million in 2022. Thus, the growing number of immunocompromised individuals is fueling the expansion of the coccidioidomycosis drug market.

Major companies operating in the coccidioidomycosis drug market are emphasizing renewed R&D investments in innovative antifungal therapies and vaccines, including chitin synthase inhibitors and next-generation systemic agents, to address rising incidence and drug resistance. A chitin synthase inhibitor is a therapeutic compound that targets fungal chitin synthase enzymes, disrupting fungal cell wall formation and reducing the survival of Coccidioides species. For example, in June 2025, Valley Fever Solutions, a US-based biotech firm, progressed NikZ (Nikkomycin Z) into Phase I/II trials; the drug offers inhalable delivery, strong chitin synthase inhibition against both acute and chronic infections, and orphan drug designations, aiming for enhanced efficacy with shorter treatment courses. Additional backing comes from government agencies: the U.S. National Institute of Allergy and Infectious Diseases (NIAID), through its 2025 Valley Fever Strategic Plan, continues to support clinical trial infrastructure, vaccine research, and antifungal innovation.

In November 2023, Basilea Pharmaceutica Ltd., a Switzerland-based biopharmaceutical firm, acquired the rights to fosmanogepix from Amplyx Pharmaceuticals Inc. for an undisclosed sum. Through this acquisition, Basilea intends to commence the first phase III study of fosmanogepix in 2024, strengthening its presence in the antifungal treatment sector and addressing the critical demand for new antifungal therapies. Amplyx Pharmaceuticals Inc. is a US-based pharmaceutical company and an affiliate of Pfizer Inc. that focuses on developing drugs for infectious diseases, including coccidioidomycosis.

Major companies operating in the coccidioidomycosis drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Viatris Inc., Teva Pharmaceuticals USA Inc., Baxter International Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc., Cipla Limited, Dr. Reddy's Laboratories, Zydus Group, Amneal Pharmaceuticals Inc., Recordati S.p.A., Glenmark Pharmaceuticals Limited, Xellia Pharmaceuticals Pvt. Ltd., Brundavan laboratories Pvt.Ltd., LGM Pharma, Enomark Pharma

North America was the largest region in the coccidioidomycosis drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coccidioidomycosis drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the coccidioidomycosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The coccidioidomycosis drug market consists of revenues earned by entities by providing services such as diagnostic testing, patient management programs, pharmacovigilance services, drug consultation and advisory, clinical trials for new treatments, and education and awareness campaigns aimed at improving diagnosis, treatment adherence and overall patient outcomes. The market value includes the value of related goods sold by the service provider or included within the service offering. The coccidioidomycosis drug market also includes sales of antifungal medications and other treatment options, along with diagnostic kits, treatment formulations, intravenous therapies, and combination drug therapies designed to manage and treat valley fever and related complications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Coccidioidomycosis Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses coccidioidomycosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for coccidioidomycosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The coccidioidomycosis drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Azoles; Echinocandins; Polyenes
• 2) By Route Of Administration: Oral; Intravenous
• 3) By Treatment Phase: Acute Phase; Chronic Phase; Prophylactic Treatment
• 4) By Group Of Patients: Immunocompetent Patients; Immunocompromised Patients
• 5) By End-User: Speciality Clinics; Hospitals; Homecare; Other End-Users
• Subsegments:
• 1) By Azoles: Fluconazole; Itraconazole; Voriconazole; Posaconazole
• 2) By Echinocandins: Caspofungin; Micafungin; Anidulafungin
• 3) By Polyenes: Amphotericin B; Liposomal Amphotericin B
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Bayer AG; Novartis AG; Viatris Inc.; Teva Pharmaceuticals USA Inc.; Baxter International Inc.; Astellas Pharma Inc.; Bausch Health Companies Inc.; Sun Pharmaceutical Industries Ltd.; Apotex Inc.; Cipla Limited; Dr. Reddy's Laboratories; Zydus Group; Amneal Pharmaceuticals Inc.; Recordati S.p.A.; Glenmark Pharmaceuticals Limited; Xellia Pharmaceuticals Pvt. Ltd.; Brundavan laboratories Pvt.Ltd.; LGM Pharma; Enomark Pharma
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Coccidioidomycosis Drug Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Coccidioidomycosis Drug Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Coccidioidomycosis Drug Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Coccidioidomycosis Drug Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Use Of Azole Antifungal Therapies
  • 4.2.2 Increasing Focus On Long-Term Antifungal Treatment
  • 4.2.3 Growing Diagnosis In Endemic Regions
  • 4.2.4 Expansion Of Hospital-Based Infectious Disease Care
  • 4.2.5 Increased Attention To Immunocompromised Patients

5. Coccidioidomycosis Drug Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Infectious Disease Clinics
• 5.3 Homecare Patients
• 5.4 Immunocompromised Patient Centers
• 5.5 Academic Medical Centers

6. Coccidioidomycosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Coccidioidomycosis Drug Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Coccidioidomycosis Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Coccidioidomycosis Drug Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Coccidioidomycosis Drug Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Coccidioidomycosis Drug Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Coccidioidomycosis Drug Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Coccidioidomycosis Drug Market Segmentation

• 9.1. Global Coccidioidomycosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Azoles, Echinocandins, Polyenes
• 9.2. Global Coccidioidomycosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Intravenous
• 9.3. Global Coccidioidomycosis Drug Market, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Acute Phase, Chronic Phase, Prophylactic Treatment
• 9.4. Global Coccidioidomycosis Drug Market, Segmentation By Group Of Patients, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immunocompetent Patients, Immunocompromised Patients
• 9.5. Global Coccidioidomycosis Drug Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Speciality Clinics, Hospitals, Homecare, Other End-Users
• 9.6. Global Coccidioidomycosis Drug Market, Sub-Segmentation Of Azoles, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Fluconazole, Itraconazole, Voriconazole, Posaconazole
• 9.7. Global Coccidioidomycosis Drug Market, Sub-Segmentation Of Echinocandins, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Caspofungin, Micafungin, Anidulafungin
• 9.8. Global Coccidioidomycosis Drug Market, Sub-Segmentation Of Polyenes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Amphotericin B, Liposomal Amphotericin B

10. Coccidioidomycosis Drug Market Regional And Country Analysis

• 10.1. Global Coccidioidomycosis Drug Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Coccidioidomycosis Drug Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Coccidioidomycosis Drug Market

• 11.1. Asia-Pacific Coccidioidomycosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Coccidioidomycosis Drug Market

• 12.1. China Coccidioidomycosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Coccidioidomycosis Drug Market

• 13.1. India Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Coccidioidomycosis Drug Market

• 14.1. Japan Coccidioidomycosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Coccidioidomycosis Drug Market

• 15.1. Australia Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Coccidioidomycosis Drug Market

• 16.1. Indonesia Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Coccidioidomycosis Drug Market

• 17.1. South Korea Coccidioidomycosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Coccidioidomycosis Drug Market

• 18.1. Taiwan Coccidioidomycosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Coccidioidomycosis Drug Market

• 19.1. South East Asia Coccidioidomycosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Coccidioidomycosis Drug Market

• 20.1. Western Europe Coccidioidomycosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Coccidioidomycosis Drug Market

• 21.1. UK Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Coccidioidomycosis Drug Market

• 22.1. Germany Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Coccidioidomycosis Drug Market

• 23.1. France Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Coccidioidomycosis Drug Market

• 24.1. Italy Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Coccidioidomycosis Drug Market

• 25.1. Spain Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Coccidioidomycosis Drug Market

• 26.1. Eastern Europe Coccidioidomycosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Coccidioidomycosis Drug Market

• 27.1. Russia Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Coccidioidomycosis Drug Market

• 28.1. North America Coccidioidomycosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Coccidioidomycosis Drug Market

• 29.1. USA Coccidioidomycosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Coccidioidomycosis Drug Market

• 30.1. Canada Coccidioidomycosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Coccidioidomycosis Drug Market

• 31.1. South America Coccidioidomycosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Coccidioidomycosis Drug Market

• 32.1. Brazil Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Coccidioidomycosis Drug Market

• 33.1. Middle East Coccidioidomycosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Coccidioidomycosis Drug Market

• 34.1. Africa Coccidioidomycosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Coccidioidomycosis Drug Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Treatment Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Coccidioidomycosis Drug Market Regulatory and Investment Landscape

36. Coccidioidomycosis Drug Market Competitive Landscape And Company Profiles

• 36.1. Coccidioidomycosis Drug Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Coccidioidomycosis Drug Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Coccidioidomycosis Drug Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. Coccidioidomycosis Drug Market Other Major And Innovative Companies

• Viatris Inc., Teva Pharmaceuticals USA Inc., Baxter International Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc., Cipla Limited, Dr. Reddy's Laboratories, Zydus Group, Amneal Pharmaceuticals Inc., Recordati S.p.A., Glenmark Pharmaceuticals Limited, Xellia Pharmaceuticals Pvt. Ltd., Brundavan laboratories Pvt.Ltd.

38. Global Coccidioidomycosis Drug Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Coccidioidomycosis Drug Market

40. Coccidioidomycosis Drug Market High Potential Countries, Segments and Strategies

• 40.1 Coccidioidomycosis Drug Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Coccidioidomycosis Drug Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Coccidioidomycosis Drug Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer